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ABSTRACT 
 
Estrogen Levels in Mice with Synthetic Estrogen Pellet Implant. 
(May 2014) 
Katherine Marie Oetken 
Department of Nutrition and Food Science 
Texas A&M University  
 
Research Advisor: Dr. Clinton Allred 
Department of Nutrition and Food Science 
 
Evidence suggests that estrogen plays a role in decreasing the risk of developing colon cancer.  
Numerous animal studies demonstrate possible mechanisms to explain how estradiol (E2) 
prevents this disease.  Many of these studies involve removing the ovaries of mice and replacing 
E2 at a controlled dose for the length of the study.  One method of E2 delivery involves 
compacting E2 and cholesterol into a pellet and implanting it subcutaneously on the back of the 
animal. While the release patters of silastic implants have been studied previously, the 
compressed powder pellets release patterns has not. It is unclear if the results of studies using 
this hormone delivery method come from a steady release of the E2 over the entirety of the study 
or if it is the result of a giant influx of E2 levels just at the beginning. This ten-week experiment 
compared the amounts of E2 released from an E2 compressed powder pellet, a silastic E2 implant 
and a control cholesterol implant. To observe the amount of estradiol released, female mice were 
first ovariectomized and received either a treatment of: E2, control, or a silastic implant of E2.  
Each week following the surgery, a group of mice were sacrificed from each of the three 
treatment groups.  The blood was tested using an ELISA test to determine the levels of estradiol.  
The results showed that there was peak of E2 directly following the implantation of the pellet and 
a week after implanting the silastic E2, but the levels then remained constant.  
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NOMENCLATURE 
 
OVX  Surgery to remove uterus  
E2  Estrogen  
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CHAPTER I 
 
INTRODUCTION 
 
 
Challenges in current research  
Research has found a correlation between estradiol (E2) and a reduced risk of colon cancer. The 
Women’s Health Initiative study compared the risk of postmenopausal women who received 
hormonal replacement treatment with a placebo group and found that those who did receive the 
hormone therapy were more resistant to colon cancer [1]. Similar results have been observed in 
animal studies. One study treated a group of mice with E2 then exposed them to carcinogens, and 
found the E2 group to have fewer tumors than animals not receiving E2 [2].  The mechanism as to 
how the E2 protects against colon cancer is not fully understood. There is data to suggest that the 
E2 plays an important role in inducing apoptosis, programmed cell death, of non-malignant 
colonocytes before they can develop into cancer. E2 is also suggested to aid in repairing DNA 
double strand breakage. Since the mechanism of how E2 protects against cancer is still 
developing, it is important to have accurate research on the topic. A common way to study this 
topic is through the use of animal models.  
 
Controlling concerns 
 To better understand the protective role of E2 observed in animal models, it is necessary to know 
the rate of exposure to E2  over time in mice supplemented with E2. The first step in many animal 
studies investigating the effects of the hormone estrogen is removing the ovaries via an 
ovariectomy. This ensures that the animals will not be producing significant levels of E2 de novo.  
Once the ovaries are removed, E2 implants are used to control the amount of E2 the animal is  
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exposed to. Commonly, the E2 implant is administered subcutaneously either in the form of an E2 
compressed powder pellet or a silastic E2 implant. The silastic E2 is more widely used and is a 
clear silicone tube that has a semi-permeable membrane that allows for the E2 to diffuse through 
the tube and into the subject. The silastic implant has previously been observed to deliver 
hormones at a slow, constant, rate. The E2 pellets are compressed E2 mixed with cholesterol that 
is pressed into a cylinder form. There is no data showing the rate at which the E2 is released from 
the pellet however it is speculated that the rate is a constant.  Both forms of the E2 implants will 
release E2 for several weeks and are generally replaced every 8 weeks of a study to ensure 
constant E2 exposure.  To test the hypothesis of how the E2 is released from the compressed 
powder pellet, the present study took weekly samples from mice that had been ovariectomized 
and received either an E2 pellet, a silastic E2 implant or a cholesterol control pellet to compare 
the plasma levels of E2 and observe the rate of E2 release.  
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CHAPTER II 
METHODS 
 
 
Collecting the data  
Animals: Female c57bl/6 mice were ovariectomized on day 0 and implanted with one of three 
treatments at the base of the neck; a control compressed cholesterol pellet, a 0.5 mg E2 + 19.5 mg 
cholesterol compressed powder pellet or a 0.5 mg E2 + 19.5 mg cholesterol silastic implant. It’s 
important to notice that the concentration of estradiol is the same for both the E2 pellet and 
silastic E2 groups. The mice were then separated into cages based on which week they would be 
sacrificed, with each cage having mice from all three treatments. Mice were sacrificed weekly by 
ketamine injection and blood was collected via cardiac puncture. Immediately after sacrifice, the 
uterus and colon were removed and the uterine weight and colon length were measured. Plasma 
was extracted from whole blood by centrifuging the samples at 2500 RPM for 15 minutes and 
then aliquoted prior to being stored at -20°C. Plasma levels of E2 were measured from these 
samples using an enzyme linked immunosorbance assay (ELISA.) 
Enzyme-linked immunosorbent assay (ELISA):  The amount of estrogen in the plasma was 
determined using an Estradiol EIA Kit (Cayman Chemicals.) This is a competitive assay that 
determines estradiol levels based on absorbance. It is based on competition between estradiol and 
an estradiol-acetylcholinesterase conjugate for a limited amount of Estradiol antiserum. To 
begin, plates are previously coated with mouse monoclonal anti-rabbit IgG and blocked with 
proteins. The antiserum-estradiol complex will bind to the monoclonal anti-rabbit IgG.  
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The plates will then be washed to discard any unbound reagents and Ellman’s Reagent will be 
added. This enzymatic reaction well reveal a yellow coloring that is directly proportional to the 
amount of Estradiol Tracer bound to the well. This amount of Estradiol Tracer is then inversely 
proportional to the amount of free estradiol present.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
CHAPTER III 
 
RESULTS 
 
Data collected 
A total of 60 mice were collected for use in this study all of them were female c57bl/6 mice. One 
of those died premature to being sacrificed and was not included in the analysis. 59 mice 
remained to be analyzed.  There were weeks with no control mice sacrificed and to get the data 
for that week it was averaged with the surrounding weeks. The data collected showed a peak in 
estradiol levels directly following the estradiol pellet implants, and a peak in estradiol levels a 
week after the silastic estradiol was implanted. Both of these treatments quickly went down to a 
steady release for the remainder of the study. The colon length showed no difference between 
any of the three treatments, however in all three treatments during the last week it’s length did 
decrease. The uterus weight increased significantly with the two estradiol groups and was much 
smaller in the control group.  
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Figure 1 
 
Figure 2  
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Figure 3 
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CHAPTER IV 
 
CONCLUSION 
 
 
The final results supported the original claim that the E2 pellet releases estradiol in a constant 
amount.  For women an estradiol level between 1-2nM is physiologically common during a 
normal menstrual cycle, and was what the study hoped to achieve in the mice model. The data 
supported this claim and showed that most the E2 pellet and silastic E2 maintained estradiol 
levels between .7-1.2nM for the duration of the study. This confirms that the results of studies 
that use the E2 pellets are not from high estradiol levels, and instead from the estradiol itself.  In 
this experiment, both the E2 pellet and silastic E2 groups had a spike in plasma estradiol levels 
following implantation. The E2 pellet’s spike was immediately following the implant, and the 
silastic E2 spike occurred a week following. After this spike, both released a steady amount of 
estradiol. This steady release of estradiol was the desired outcome. In addition to studying the 
plasma E2 levels the colon lengths and uterus weight was measured to observe the effects. The 
colon length remained constant for the majority of the study until the final week when there was 
a slight decrease in length. This suggests that estradiol has little effect on the colon length since 
in both the E2 group and cholesterol group there was no noticeable difference. Finally, as 
expected the E2 treated groups had larger uterine weights than the control group due to atrophy 
of the uterus in the absence of E2.  
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